Mixed Results From ReGenTree's DES Therapy In Second Phase III

ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.